
MEDLINE
Arglaes provides a seven-day, non-cytotoxic barrier against infection
To open, break perforation and bend top of box back.
NDC: 53329-300-34
MEDLINE
Sterile*
Arglaes™ Film
Antimicrobial Barrier Film Dressing
Reorder: MSC9023
• Ionic silver from a controlled-release barrier film
• Non-cytotoxic
• Effective for 7 days
Ag+
2 3/8 in x 3 1/8 in (6 cm x 8 cm)
Contents: 10 Dressings per Box
Sterile*
Arglaes™ Island
Antimicrobial Barrier Film Dressing with Alginate Pad
Ag+
Arglaes® Controlled-Release Silver Technology

Reduce bioburden with Arglaes® Antimicrobial Silver Barrier Dressings

Arglaes began the antimicrobial silver revolution as the first product to provide controlled-release, ionic silver for up to seven days.

Arglaes technology utilizes ionic silver to create an environment hostile to bacteria and fungi, but completely non-cytotoxic. The sustained-activity ionic silver maintains full efficacy for up to seven days. The Arglaes technology is available as a transparent film dressing, with and without an alginate pad. The film has a high moisture vapor transmission rate. Arglaes Powder is well suited for difficult-to-dress wounds as its alginate base forms a soft, conforming gel when it contacts wound exudate.

Reduces bioburden
Effective against a broad spectrum of bacteria and fungi (including MRSA, VRE and *E.coli.)*.

Constant antimicrobial protection
Controlled-release antimicrobial silver.

Non-cytotoxic
Controlled-release polymers deliver small, non-cytotoxic amounts of silver that kill bacteria and fungi, but do not harm healthy tissue.

Extended wear time
Effective for up to seven days.

Reduce costs
Dramatically reduces costs associated with treating infections.

No known resistance
Ionic silver has shown no known resistance to any bacteria or fungi, including antibiotic resistant bacteria.

The Arglaes family

Arglaes Film

Ideal for post-op and line sites
Arglaes Film is perfect for managing bioburden on line sites, post-operative incisions and donor sites. Up to seven-day wear time

Arglaes Island

Manages fluid and bioburden
Arglaes Island features a calcium alginate pad for fluid management in addition to controlled-release silver. Up to 5-day wear time.

Arglaes Powder

Ideal for deep, tunneling and highly exudating wounds
Arglaes Powder combines controlled-release silver with an alginate powder to offer bioburden reduction and fluid management to virtually any size, shape or depth of wound. Up to five-day wear time.

Arglaes in wound care

Arglaes Powder delivers controlled-release antimicrobial silver to any size, shape or depth of wound.

As Arglaes Powder mixes with wound exudate, it turns into a gel that adheres to the wound bed

Any size. Any shape. Any depth. No matter what the wound[1], use Arglaes Powder and you'll reduce the risk of infection.

Utilizing controlled-release polymers, Arglaes Powder delivers a constant stream of antimicrobial silver ions into the wound over a period of five days.

Continuous delivery, at a constant rate, means that only minute quantities of silver ions are required to maintain a continuous antimicrobial barrier without cytotoxicity.

In addition, Arglaes Powder contains alginate to aid in fluid handling. As the powder mixes with wound exudate, it turns into a gel that adheres to the wound bed and is easily removed during wound irrigation.

Arglaes Powder is easily combined with other dressings to create a system for bioburden control and optimal moist wound healing.

[1] See indications

Arglaes in the operating room

Arglaes Film and Arglaes Island offer post-operative infection control.

Post-operative infections are obviously a major problem in terms of trauma to the patient and the costs associated with treating the infection. Arglaes can help protect incision sites by providing up to a seven-day barrier against infection.

Arglaes is indicated for a variety of post-operative settings including:

- Sternotomy
- CABG procedures
- FEMPOP procedures
- Open-heart procedures
- Long-term catheters
- Skin grafts
- Donor sites
- Tram flap

"We had about a 1½% rate of sternal wound infections. Since we started using the Arglaes dressings, we have not had a deep sternal infection. Arglaes has significantly reduced our complication rate and I would recommend it for any program doing cardiac surgery."

Edward Pottmeyer, M.D.
Cardiothoracic Surgeon , Mercy Medical Center, Redding, CA

Arglaes Island applied on a sternal incision.

Arglaes Film (4" x 4¾") applied on a minimally invasive incision for saphenous vein harvesting.

Arglaes Island (4" x 4¾") applied on a minimally invasive sternal incision.

Arglaes on line sites

Arglaes Film helps provide a barrier against infection on line sites.

Infections on line sites are a costly problem to treat. Arglaes Film provides an easy-to-use and effective barrier against line site infections. Simply apply as you would a transparent film, and Arglaes delivers controlled-release silver, inhibiting the growth of bacteria and fungi, for up to seven days.

Arglaes Film applied on a line site.

Arglaes Clinical Information

Zones of Inhibition from Sustained Antimicrobial Activity

Experiments were conducted to assess the antimicrobial activity of a controlled-release silver compound against a range of microbiological species. Each species was selected because of its significance as a potential pathogen.

Agar plates inoculated with the test organisms were prepared and 10mm discs of the controlled-release silver compound and a known positive control of povidone iodine were placed on a series of separate plates.

Zones of inhibition were recorded at 24 hours, 48 hours and 7 days.

Arglaes Zone of Inhibition Study (in mm)

Organism	24 hours			48 hours			7 days		
	Arglaes	Inadine (Povidone Iodine)	Fertility Control	**Arglaes**	Inadine (Povidone Iodine)	Fertility Control	**Arglaes**	Inadine (Povidone Iodine)	Fertility Control
Proteus vulgaris	11.3	12.1	+++	10.2	5.2	+++	9.3	2.9	+++
Acinetobacter baumanii	14.8	6.8	+++	10.2	4.0	+++	10.5	3.8	+++
Enterococci faecium	9.2	0.0	+++	8.8	0.0	+++	9.5	1.2	+++
Serratia marcescens	9.0	4.4	+++	7.5	0.0	+++	7.3	0.0	+++
Candida albicans	13.5	15.1	+++	13.1	8.2	+++	15.6	3.8	+++
Pseudomonas aeruginosa	9.7	1.4	+++	8.9	0.0	+++	8.0	0.0	+++
Proteus mirabilis	8.8	6.9	+++	8.1	5.7	+++	9.9	5.9	+++
Staphylococcus aureus	14.7	0.0	+++	13.5	0.0	+++	13.4	0.0	+++
Escherichia coli	7.5	0.7	+++	6.9	0.6	+++	6.7	0.0	+++
Enterobacter cloacae	5.4	8.0	+++	5.1	0.0	+++	4.8	0.0	+++
Staphylococcus aureus (MRSA, NCTC 12493*)	20.0	10.6	+++	20.5	0.0	+++	20.3	0.0	+++
Klebsiella Edwardsii var Edwardsii	11.3	12.1	+++	10.2	5.2	+++	9.3	2.9	+++
Staphylococcus aureus (MRSA, NCTC 12232*)	13.9	2.6	+++	12.8	1.7	+++	12.5	1.5	+++
Staphylococcus epidermidis	16.0	0.0	+++	15.7	0.0	+++	22.1	0.0	+++

**National Collection Type Culture Catalog. Independent study performed by Wickham Laboratories Limited, Hampshire, England*

Antimicrobial Activity

Six separate experiments have been completed to test the in vitro activity of controlled-release barrier film dressing (Arglaes) and adhesive, which also contains controlled-release compound.

Results from all six studies confirmed the antimicrobial activity of the controlled-release barrier film dressing against the pathogens commonly associated with wound infections.

Pathogens tested include: *Staphylococcus aureus, Escherichia coli, Faecal streptococcus.*

Sustained-Release Activity of Arglaes



Independent study performed by Wickham Laboratories Limited, Hampshire, England

Illustration of Controlled-Release Polymers

Arglaes provides an antimicrobial barrier for up to seven days. Silver ions are released at a constant rate, providing a barrier that inhibits the growth of new bacteria and helps prevents the migration of already existing bacteria.







Illustrations shown here are representations of sustained-activity antimicrobial barrier effect.

Arglaes Product Information

Indications

- Pressure ulcers (Stage I-IV)
- Partial and full thickness wounds
- Leg ulcers
- Diabetic ulcers
- Central lines, CVPs and PICC lines (Arglaes Film only)
- Surgical wounds
- Grafted wounds (Arglaes Powder only)
- Donor sites
- Lacerations and abrasions
- 1st and 2nd degree burns

Contraindications

- Third degree burns
- Individuals with a known sensitivity to silver
- As a surgical implant

Change Frequency

- Arglaes Film may be left in place for up to 7 days.
- Arglaes Island and Arglaes Powder may be left in place for up to 5 days.
- Dressing change frequency will depend upon the amount of exudate.

Arglaes Ordering Information

Item No.	Description	Packaging
MSC9023	Film, 2⅜" x 3⅛"	10/bx, 100/cs
MSC9045	Film, 4" x 4¾"	10/bx, 100/cs
MSC9069	Film, 4¾" x 10"	10/bx, 50/cs
MSC9314	Film, 3" x 14", Post-Op Style	10/bx, 50/cs
MSC9123	Alginate Island, 2⅜" x 3⅛", 1" x 2" pad	10/bx, 100/cs
MSC9145	Alginate Island, 4" x 4¾", 2" x 2" pad	10/bx, 100/cs
MSC9169	Alginate Island, 4¾" x 10", 2¾" x 8" pad	10/bx, 50/cs
MSC9210	Powder, 10 gm bottle	5/bx, 20/cs
MSC9210SP	Powder, 10 gm bottle in Sterile Pouch	5/bx, 20/cs
MSC9205	Power, 5 gm bottle	5/bx, 20/cs

1-800-MEDLINE | www.medline.com

© 2003 Medline Industries, Inc., Mundelein, Illinois 60060

Medline is a registered trademark of Medline Industries, Inc. Arglaes is a registered trademark of Giltech, Ltd.

MKT2033/LIT034/20M